Skip to main content
Article thumbnail
Location of Repository

Hypoxia inducible factor-1α correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma

By Gordana Đorđević, Koviljka Matušan-Ilijaš, Emina Babarović, Ita Hadžisejdić, Maja Grahovac, Blaženka Grahovac and Nives Jonjić
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2005). BD: A combination of molecular cytogenetic analyses reveals complex genetic alterations in conventional renal cell carcinoma. Cancer Genet Cytogenet
  2. (2000). Bedossa P: Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch
  3. (2007). Cavazzana A: Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression.
  4. (2001). Fox SB: Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res
  5. (2004). Gultekin EY: Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma.
  6. (2006). Hedberg Ylva, Grankvist Kjell, Rasmuson Torgny, Bergh Anders, Ljungberg Börje: Hypoxia-inducible factor 1 alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol
  7. (1999). HJ: Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors.
  8. (2008). Influence of microvascular endothelial cells on transcriptional regulation of proximal tubular epithelial cells.
  9. (2007). Jonjic N: Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathol Res Pract
  10. (2002). Jr: Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell
  11. (2008). Kanetake H: Lymphangiogenesis and angiogenesis in conventional renal cell carcinoma: association with vascular endothelial growth factors A to D immunohistochemistry. Urology
  12. (2004). Ljungberg B: Expression of vascular endothelial growth factor protein in human renal cell carcinoma.
  13. (2006). Ljungberg B: Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol
  14. (2007). Modern therapeutic approaches in Metastatic Renal cell carcinoma. EAU-EBU Update series
  15. (2004). Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol
  16. (2007). MW: The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal
  17. (2007). Pantuck AJ, Belldegrun AS: Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res
  18. (2005). Patard JJ: Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer. Prog Urol
  19. (2005). Petrova TV: Lymphangiogenesis in development and human disease. Nature
  20. (1982). Prognostic significance of morphologic parameters in renal cell carcinoma.
  21. (2002). RD: The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell
  22. (2004). Sesterhenn IA: WHO Classification of Tumours.
  23. (2006). SJ: VEGF-C promotes survival in podocytes.
  24. (2005). Targeting the vascular endothelial growth factor pathway in renal cell carcinoma: a tissue array based analysis.
  25. (2007). The significance of VEGF-C/VEGFR-2 interaction in the neovascularization and prognosis of nephroblastoma (Wilms' tumour). Histopathology
  26. (1971). Tumor angiogenesis: therapeutic implications.
  27. (1999). Vascular endothelial growth factor induces nephrogenesis and vasculogenesis.
  28. (2005). Wall E van der: Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.